User profiles for Sophie Trouillet-Assant
 | Sophie Trouillet-AssantVerified email at chu-lyon.fr Cited by 6544 |
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
…, P Peterson, L Lorenzo, L Bizien, S Trouillet-Assant… - Science, 2020 - science.org
INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid …
[HTML][HTML] Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
…, T Defrance, J Marvel, T Walzer, S Trouillet-Assant - Nature, 2021 - nature.com
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine 1 , 2 ,
European health authorities recommended that patients under the age of 55 years who …
European health authorities recommended that patients under the age of 55 years who …
[PDF][PDF] Type I IFN immunoprofiling in COVID-19 patients
Funding-Quanterix provided the kits for this study free of charge. 37 Conflict of interest–Pons
S, Oriol G, Brengel-Pesce K, Mouton W, Compagnon C are Biomérieux® 38 employeers. …
S, Oriol G, Brengel-Pesce K, Mouton W, Compagnon C are Biomérieux® 38 employeers. …
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
…, F Cognasse, J Troya, S Trouillet-Assant… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
…, J Troya, S Trouillet-Assant… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
[HTML][HTML] Distinct evolution of SARS-CoV-2 Omicron XBB and BA. 2.86/JN. 1 lineages combining increased fitness and antibody evasion
…, D Veyer, H Péré, B Lina, S Trouillet-Assant… - Nature …, 2024 - nature.com
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral
sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.…
sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.…
[PDF][PDF] Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia
A Pizzorno, B Padey, T Julien, S Trouillet-Assant… - Cell Reports …, 2020 - cell.com
In the current COVID-19 pandemic context, proposing and validating effective treatments
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …
Polyclonal expansion of TCR Vβ 21.3+ CD4+ and CD8+ T cells is a hallmark of multisystem inflammatory syndrome in children
Multisystem inflammatory syndrome in children (MIS-C) is a delayed and severe complication
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that strikes …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that strikes …
[HTML][HTML] Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
…, F Morfin, T Walzer, S Trouillet-Assant - Journal of Experimental …, 2021 - rupress.org
IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…
Prior SARS-CoV-2 infection enhances and reshapes spike protein–specific memory induced by vaccination
…, S Paul, T Walzer, S Trouillet-Assant… - Science Translational …, 2023 - science.org
The diversity of vaccination modalities and infection history are both variables that have an
impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more …
impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more …